About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a Centers for Disease Control and Prevention report released today. According to the report, among U.S. adults aged 18-64 who were prescribed medication in the past 12 months, the percentage who did not take their medication as prescribed, asked their doctor for a lower-cost medication, or used alternative therapies to reduce prescription drug costs decreased from 2013 through 2015, and then remained relatively constant from 2015 through 2017. In 2017, strategies for reducing prescription drug costs were most commonly practiced among those who were uninsured, as 39.5 percent asked their doctor for a lower-cost medication and 13.9 percent used alternative therapies. Women were more likely than men to use these strategies, according to the report. 
 
AHA has recommended a number of policy solutions to restrain drug prices, from addressing anticompetitive actions by brand-name drug manufacturers to speeding up generic drug approvals and passing the CREATES Act.
 

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…